Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nuts! Genentech Halts Enrollment In Xolair Peanut Allergy Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm, with collaborators Novartis and Tanox, vows to continue development of the new indication for omalizumab.

You may also be interested in...

Genentech's Acquisition Of Tanox Does Not Represent A Strategic Shift, CEO Says

Genentech will continue to set a "high bar" for acquisitions after buying Xolair partner Tanox for $919 mil., firm says.

Tarceva Pancreatic Cancer Indication Turned Down In The EU

Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts